The Effect on Federal Spending of Legislation Creating a Regulatory Framework for Follow-on Biologics: Key Issues and Assumptions

  • Recommend
  • Tweet
  • Print
  • Email

Legislative proposals to create an expedited pathway for review of follow-on biologic drugs (“FOBs”; also called biosimilars) have generated much debate about potential cost savings, with estimates of federal budget savings over ten years of $3.6 to $14.1 billion.

This very broad range reflects substantial uncertainty about a number of critical assumptions underlying such forecasts, and policymakers should therefore proceed cautiously in assessing the potential impacts of legislation establishing an expedited pathway for FOBs.

Read the white paper

Hide Date: